The rigid steroid 21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP) is a dissociated glucocorticoid receptor modulator potentially useful as a novel coadjuvant in breast cancer chemotherapy by Orqueda, Andres Javier et al.
Accepted Manuscript
Title: The rigid steroid 21-hydroxy-6,19-epoxyprogesterone
(21OH-6,19OP) is a dissociated glucocorticoid receptor
modulator potentially useful as a novel coadjuvant in breast
cancer chemotherapy
Author: Andres J. Orqueda M. Virginia Dansey Alejandro
Espan˜ol Adriana S. Veleiro Elisa Bal de Kier Joffe M. Elena
Sales Gerardo Burton Adali Pecci
PII: S0006-2952(14)00230-5
DOI: http://dx.doi.org/doi:10.1016/j.bcp.2014.04.006
Reference: BCP 11954
To appear in: BCP
Received date: 31-1-2014
Revised date: 2-4-2014
Accepted date: 2-4-2014
Please cite this article as: Orqueda AJ, Dansey MV, Espan˜ol A, Veleiro AS, Joffe EBK,
Sales ME, Burton G, Pecci A, The rigid steroid 21-hydroxy-6,19-epoxyprogesterone
(21OH-6,19OP) is a dissociated glucocorticoid receptor modulator potentially useful as
a novel coadjuvant in breast cancer chemotherapy, Biochemical Pharmacology (2014),
http://dx.doi.org/10.1016/j.bcp.2014.04.006
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Page 1 of 43
Ac
ce
pte
d M
an
us
cri
pt
1 
 
The rigid steroid 21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP) is a 
dissociated glucocorticoid receptor modulator potentially useful as a novel 
coadjuvant in breast cancer chemotherapy  
 
Andres J Orquedaa,c, M Virginia Danseyb,c, Alejandro Españole, Adriana S Veleirob,d, Elisa Bal de 
Kier Joffef, M Elena Salese, Gerardo Burtonb,d and Adali Peccia,c 
 
aDepartamento de Química Biológica and bDepartamento de Química Orgánica; cIFIBYNE and 
dUMYMFOR (CONICET), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, 
Ciudad Universitaria (C1428EGA), Buenos Aires, Argentina. 5CEFyBo (CONICET) and 6Área 
Investigación Instituto de Oncología Ángel H. Roffo, Facultad de Medicina, Paraguay 2155 
(C1121AB), , Universidad de Buenos Aires, Buenos Aires, Argentina 
 
AJO: aorqueda@qb.fcen.uba.ar; MVD: virg_dansey@hotmail.com; AE: aespan_1999@yahoo.com;  
ASV: adrianav@qo.fcen.uba.ar; EBdeKJ: balelisa2002@yahoo.com.ar; MES: malegazpio@yahoo.com.ar; GB: 
burton@qo.fcen.uba.ar; AP: apecci@qb.fcen.uba.ar 
 
Address correspondence to: Prof. Dr. Adali Pecci, Departamento de Química Biológica, Facultad de Ciencias 
Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires C1428EGA, Argentina. Phone/Fax: 54-11-
4576-3342, e-mail: apecci@qb.fcen.uba.ar; pecciadali@gmail.com 
Page 2 of 43
Ac
ce
pte
d M
an
us
cri
pt
2 
 
Abstract 
Glucocorticoids (GCs) are steroid hormones widely used as coadjuvants in the treatment of solid 
tumors due to their anti-inflammatory effects. However, evidence show that they also may induce 
chemotherapy resistance, probably through their capacity to inhibit apoptosis triggered by 
antineoplastic drugs. GCs exert their action by regulating gene expression throughout two main 
mechanisms: transactivation, where the activated glucocorticoid receptor (GR) directly binds to 
certain genes; and transrepression, an indirect mechanism by which GR regulates other transcription 
factors activities. Recently, our group has shown that the rigid steroid 21-hydroxy-6,19-
epoxyprogesterone (21OH-6,19OP) is a selective GR ligand that behaves as an agonist in 
transrepression assays and as an antagonist in transactivation ones. Here, we have evaluated the 
anti-inflammatory activity of 21OH-6,19OP, its capacity to generate chemoresistance, as well as its 
mechanism of action. We found that 21OH-6,19OP inhibits nitrites formation and the inducible 
nitric oxide synthase (Nos-2) expression in macrophages. It also blocks the expression of both 
cyclooxygenase-2 (COX-2) and interleukin-8 (IL-8) triggered by tumor necrosis factor-alpha (TNF-
α) in epithelial lung cancer cells. However, contrary to dexamethasone (DEX), 21OH-6,19OP 
neither reverts the paclitaxel-induced caspase-3 activity, nor induces the anti-apoptotic Bcl-XL gene 
expression in murine tumor mammary epithelial cells; and importantly, it lacks GCs-associated 
chemoresistance in a mouse mammary tumor model. Together, our findings suggest that 21OH-
6,19OP behaves as a dissociated GC that keeps anti-inflammatory action without affecting the 
apoptotic process triggered by chemotherapeutic drugs. For these reasons, this steroid may become 
a putative novel coadjuvant in the treatment of breast cancer. 
Key words: GCs, glucocorticoids; GR, glucocorticoid receptor; 21OH-6,19OP, 21-hydroxy-6,19-
epoxyprogesterone; MKP-1, mitogen activated protein kinase phosphatase-1; COX-2, cyclooxygenase-2; 
BCL-XL, B cell lymphoma factor X large. 
Chemical compounds studied in this article: Dexamethasone (PubChem CID: 5743); Paclitaxel (PubChem 
CID: 36314).  
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1. Introduction 
    GCs are essential steroid hormones that affect multiple organ systems throughout different 
pleiotropic functions such as the depression of the immune system, the repression of inflammation, 
activation of glucose mobilization in the fasting state, cell growth, apoptosis and differentiation. 
Synthetic glucocorticoid analogs are widely prescribed as immune suppressant/anti-inflammatory 
agents, being often components of chemotherapy regimes used in the treatment of lymphatic 
malignancies due to their potent pro-apoptotic properties on these cells [1-2]. They are also 
administered as anti-emetic, anti-pyretic and anti-hypersensitivity agents before treatment of solid 
tumors with chemotherapeutic drug [1-4]. However, despite their high anti-inflammatory efficacy, 
the therapeutic use of GCs is often restrained due to their severe side effects that accompany long-
term treatments. In fact, the use of GCs as components of chemotherapy regimes has been alerted 
by several clinical studies, which indicate that, in spite of alleviating toxic effects on healthy tissue, 
administration of GCs before chemotherapy induces resistance to treatment, probably due to their 
ability to trigger anti-apoptotic signals on epithelial cells [1]. 
    GCs exert their multiple effects mainly through their interaction with the GR, a hormone-
activated transcription factor essential for life [5-6]. The GR contains three distinct functional 
domains: the transactivation domain AF-1, the DNA-binding domain and the ligand binding domain 
[7-8]. In the absence of hormone, GR primarily localizes in the cytoplasm bound to a protein 
complex that includes heat shock protein (HSP) 70 , HSP90 and immunophilins, while upon ligand 
binding the activated GR is mainly nuclear [9]. Once in the nucleus, GR regulates gene expression 
directly by binding to specific DNA sequences or by the interaction and modulation of other 
transcription factors [10]. These two main mechanisms of action were historically named GR 
transactivation and GR transrepression, respectively [11]. Interestingly, a leading hypothesis 
proposes that those beneficial effects of GCs would be associated with indirect transrepression 
mechanisms, whereas rescue from chemotherapy dependent cell death would be associated with 
direct transactivation [12]. Thus, the main goal in drug research of GRs was to chemically alter the 
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ligand properties in order to selectively modulate receptor activities. In the case of GCs, recent 
advances in the study of the molecular mechanisms of GR action, together with simulation of the 
ligand interaction with the tertiary structure of the GR ligand binding domain by molecular 
dynamics, have promoted increasing interest in the development of dissociated GR modulators that 
can alter specifically certain GR activities in order to exclusively favor the beneficial effects of GCs 
[13]. 
    In previous work, we reported the synthesis of new pregnane-derivatives and the screening of 
their ability to regulate different glucocorticoid parameters as apoptosis in thymocytes, tyrosine-
aminotransferase activity in hepatocytes and MMTV- and κB-reporter induction. One of these 
compounds, 21OH-6,19OP, is a synthetic conformationally rigid highly bent pregnane steroid that 
lacks the bulky substituent at C-11 found in active antagonists of the GR [14]. 21OH-6,19OP 
behaves as a selective GC since it efficiently displaces [3H]corticosterone from thymus-GR but 
neither competes with [3H]aldosterone binding to kidney-mineralocorticoid receptor nor with 
[3H]progesterone binding to uterus-progesterone receptors [14]. Upon GR binding, 21OH-6,19OP 
activates translocation of the receptor to the nucleus and its dimerization [15]. This rigid steroid has 
the potential function of a dissociated GC since it inhibits Rel A and activator protein 1 (AP-1) 
dependent gene expression in BHK and Cos-1 cells [15-16] but it is unable to induce tyrosine 
aminotransferase or to increase glycogen deposits in rat liver [14] and MMTV-LUC reporter gene 
expression in L929 fibroblasts [17] and in Cos-1 cells transfected with the GR receptor [16]. 
Moreover, when 21OH-6,19OP was co-incubated with corticosterone or DEX, it antagonized the 
transactivation pathway [14,16]. 21OH-6,19OP also behaves as a strong anti-glucocorticoid, 
blocking DEX-dependent apoptosis in thymocytes [17]. 
    Taking these results into account, the aim of the present work was to evaluate the anti-
inflammatory properties of 21OH-6,19OP, as well as its ability to promote cell-survival in 
mammary tumor cells. According to the results, 21OH-6,19OP arises as a dissociated 
glucocorticoid with potent anti-inflammatory effects in macrophages and epithelial lung cancer 
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cells. Moreover, at variance with DEX, the rigid steroid did not generate chemoresistance, since it 
was unable to prevent apoptosis and the antitumoral effect induced with the chemotherapeutic agent 
paclitaxel (PTX) in mammary tumor cancer cells. 
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2. Materials and Methods 
2.1. Reagents and hormones: TNF-α was purchased from Thermo Scientific (Rockford, USA). 
Lipopolysaccharide (LPS), interferon-gamma (INF-γ), DEX, dimethyl sulfoxide (DMSO), PTX, 
NaNO2 and Griess reagents were purchased from Sigma (St. Louis, USA). Minimum Essential 
Medium (MEM), RPMI 1640 media, penicillin-streptomycin, Trizol reagent, deoxynucleotide 
triphosphates, random primers, MgCl2 and Taq polymerase were from Invitrogen (Carlsbad, CA, 
USA) and fetal bovine serum (FBS) from Internegocios S.A. (Buenos Aires, Argentina). Specific 
oligonucleotides were from Genbiotech (Buenos Aires, Argentina. Sybr Green from Roche 
(Indianapolis, IN, USA). Acrylamide/bisacrylamide, Moloney murine leukemia virus reverse 
transcriptase (MMLV), RNasin , EDTA, EGTA, Hepes, β-mercaptoethanol, dithiothreitol (DTT), 
Triton X-100, SDS, digitonin , β-glycerophosphate and Tris were from Promega (Madison, WI, 
USA). Caspases substrate acetyl-Asp-Glu-Val-Asp-7-amino-4 p-nitroanilide (Ac-DEVDpNA) and 
proteases inhibitors were from Calbiochem (San Diego, CA, USA). Charcoal-stripped FCS was 
prepared with charcoal-dextran as described elsewhere [18]. All solvents and formaldehyde used in 
this work were from Cicarelli (San Lorenzo, Argentina); inorganic salts were purchased from 
Biopack (Pcia. de Buenos Aires, Argentina). 21OH-6,19OP was prepared as previously described 
[14,19]. For in vitro experiments, LPS and DEX were dissolved in sterile water and ethanol, 
respectively, and 21OH-6,19OP and paclitaxel, in DMSO; compounds were prepared as 1000X 
stock solution and store at -20°C. 
2.2. Cell cultures: Both the human lung cancer cell line A549 (American Type Culture Collection, 
Virginia, USA) and murine mammary tumor cell line LM3 [20] were cultured in MEM 
supplemented with 5% FBS containing 100 IU/ml penicillin and 100 μg/ml streptomycin. Raw 
264.7 murine macrophage cell line (American Type Culture Collection, Virginia, USA) was 
cultured in RPMI 1640 supplemented with 10 % FBS, 100 IU/ml penicillin and 100 μg/ml 
streptomycin. Cells were maintained at 37 °C in a humidified atmosphere with 5% CO2.  
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2.3. Preparation of peritoneal macrophages: Peritoneal macrophages from female BALB/c mice 
were suspended in Hank´s balanced salt solution (1 g/l glucose; 8 g/l NaCl; 0,4 g/l KCl; 0,06 g/l 
H2KPO4; 0,053 g/l HNa2PO4; 0,35 g/l NaHCO3; pH 7,2); after washing twice with ice cold sterile 
PBS, cells were plated in 24 wells plates in RPMI 1640 medium containing 10% FBS, 100 IU/ml 
penicillin/streptomycin and incubated for 2 h at 37◦C in 5% CO2 humidified incubator. Then, non-
adherent cells were removed by gently washing with PBS and freshly prepared medium was added. 
2.4. Animals and treatments. Female 12 week-old BALB/c mice were purchased from the School 
of Veterinary Sciences from the University of Buenos Aires. Mice were maintained under specific 
pathogen-free conditions, and all experiments were performed in accordance with the U.S. Public 
Health Service Policy on Humane Care and Use of Laboratory Animals and approved by the 
Institutional Animal Care and Use Committee from the University of Buenos Aires. Mammary 
tumors were developed by subcutaneous implantation (s.c) of LM3 cells (4x105) into the right 
flanks of the mice. At day 7 post-inoculation, when tumors were palpable, mice were randomly 
divided into 4 groups (8 mice per group) and treated with different regimes on day 0: a) 10 mg/kg 
PTX (i.p); b) 0.2 mg/kg DEX in combination with 15 mg/kg PTX, i.p; c) 25 mg/kg 21OH-6,19OP 
in combination with 10 mg/kg PTX, i.p; d)Vehicle (VEH) was also prepared as control treatment. 
The concentration of each compound was decided according to previous reports [21-22]. Steroids 
were administered 1 h before PTX injection. PTX was diluted in MEM with 15 % DMSO while 
steroids were diluted in etanol:propilenglicol:sesame oil (1:1:11.5).These regimes were repeated 
every 2 days for a total of 5 cycles. Each animal was ear-marked and followed individually 
throughout the experiments. Two perpendicular lengths (width, w, and length, l) of the tumors were 
measured every 3 days until the animals were sacrificed. Tumor diameters (D) were calculated 
using the following formula: lwD ⋅= . The curve of tumor growth was drawn based on tumor 
diameter (mm) versus time of treatment (days). Tumors were fixed in 10 % formalin and embedded 
in paraffin. Five μm tumor sections were stained with hematoxilyn and eosin for histopathological 
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studies and mitosis counting. The presence of spontaneous metastasis was assessed by histological 
examination of lung sections. 
For the analysis of Cox-2 in vivo expression, mice were injected i.p. with 5 mg/kg LPS (diluted in 
PBS), 2 mg/kg DEX, 25 mg/kg 21OH-6,19OP (both steroids prepared same as before) or vehicles. 
After 16 h, peritoneal macrophages were harvested as described above and then plated (5 x105 cells) 
in 24 well dishes in RPMI 1640 supplemented with 25 mM Hepes and 10 % charcoal-stripped FBS. 
Two hours later cells were washed 3 times with PBS and incubated for another 2 h; finally total 
RNA was prepared. 
For histological analysis, tumors were fixed in 10% neutral buffered formaldehyde, embedded in 
paraffin, sectioned at 7 μm and routinely stained with hematoxylin-eosin (H&E). Mitotic figures 
from each tumor section were counted and the presence of parenchymal metastatic nodules in lung 
sections was determined using a conventional light microscope. 
2.5. Plasmids and transfections. Plasmids encoding p65 activated subunit of nuclear factor-κ B 
(NF-κB) [23] and cJun activated subunit of AP-1 (kindly provided by Dr. Coso [24]) were used for 
transient transfection assays. A549 cells were transiently transfected with Lipofectamine 2000 
(Invitrogen) according to manufacturer´s instructions. Briefly, 3x105 cells were plated in 6 well 
plates in growth medium without antibiotics. Twenty-four hours later cells were incubated in the 
presence of 4 μg plasmids mixed with Lipofectamine for 24 h. Finally, cells were starved overnight 
and stimulated for 16 h with steroids or vehicle. 
2.6. Caspase-3-like activity assay: The assay was performed as previously described [25]. Briefly, 
3.5x105 LM3 cells were plated in p60 plates; after 48 h cells were treated for 36 h with 10 μM PTX, 
1 μM DEX or 10 μM 21OH-6,19OP in MEM supplemented with 1 % charcoal-stripped FBS and 
antibiotics. Cells were harvested in lysis buffer (50 mM Tris–HCl pH 7.4 containing 1 mM EDTA, 
10 mM EGTA, 10 μM digitonin, 0.5 mM PMSF, 1.5 μM aprotinin and 14.6 μM pepstatin) for 30 
min at 37 °C. Cellular extracts were clarified by centrifugation at maximum speed and 150 μl of the 
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resultant supernatant were incubated with 146 μl of incubation buffer (100 mM HEPES pH 7.5, 
20% glycerol, 0.5 mM EDTA and 5 mM dithiothreitol (DTT)) plus 4 μl of Ac-DEVDpNA substrate 
(100 μM) at 37 °C for 5 h. Blanks were also run, containing either the substrate or the cellular 
extract alone, to deduct in each case. Caspase-catalyzed release of the chromophore pNA from the 
substrate was measured at 405 nm with a multiplate spectrophotometer (Benchmark, Bio-Rad, 
Hercules, CA, USA) and the cleavage activity was expressed as pNA absorbance units per mg 
protein. Protein concentration was determined by the method of Bradford [26] using bovine serum 
albumin as a standard. 
2.7. Cell viability by crystal violet staining. The number of viable cells attached to the culture 
plate at the end of each treatment was evaluated by crystal violet staining. Briefly, LM3 cells 
(1x104) were plated in 96-multiwell plates and allowed to grow for 48 h. Then, apoptosis was 
induced by treating cells with 10 μM PTX for 48 h in MEM supplemented with 1 % charcoal-
stripped FBS and antibiotics. After this, cells were fixed with 100 μl ice-cold glutaraldehyde (1.1% 
in PBS) for 15 min at 4 °C, washed three times by submersion in de-ionized water, air-dried, and 
stained for 20 min with 100 μl of crystal violet 0.1% in 200 mM phosphoric acid, pH=6. After 
careful aspiration of the crystal violet solution, extensive washing with de-ionized water eliminated 
the excess of dye. Then, samples were air-dried and treated with 100 μl of acetic acid 10% for 30 
min at room temperature. Optical density was measured at 595 nm with a multiplate 
spectrophotometer (Benchmark, Bio-Rad, Hercules, CA, USA). 
2.8. Protein analysis by western blot. For inflammation experiments, A549 cells seeded in 6 well 
plates were incubated for 2 h with 10 ng/ml TNF-α with or without 0.1 μM DEX or 10 μM 21OH-
6,19OP. For chemoresistence experiments, LM3 cells were seeded in 6 well plates and incubated 
for 5 h with 10 μM PTX in the presence or absence of 0.1 μM DEX or 10 μM 21OH-6,19OP. Then, 
total proteins were extracted in RIPA protein extraction buffer (50 mM Tris–HCl, 150 mM NaCl, 
1% triton, 0.25% sodium deoxycholate, 1 mM EDTA pH 7.4) supplemented with protease (Protease 
Page 10 of 43
Ac
ce
pte
d M
an
us
cri
pt
10 
 
inhibitor cocktail set I, Calbiochem) and phosphatase inhibitors (1mM NaF, β-glycerophosphate 
and 1 mM Na2VO4). The lysates were centrifuged at 12500 ×g and 4 °C for 15 min, and the pellet 
discarded. Cleared lysates were combined with SDS sample buffer (50 mM Tris pH 6.8, 1% SDS, 
0.1% bromophenol blue, 10% glycerol, 100 mM DTT). For western blot samples were boiled for 5 
min and electrophoresed for 3 h at 100 V in 15% SDS-polyacrylamide gel, transferred to a PVDF 
membrane (Bio-Rad, Hercules, CA, USA) by electroblotting in transfer buffer containing 20% 
methanol , 0.19 M glycine, 0.025 M Tris-base (pH 8.3) at 300 mA for 1.5 h at 0 °C. Blots were 
blocked 1 h at room temperature in TBS (20 mM Tris–HCl, pH 7.5, 500 mM NaCl) containing low-
fat powered milk (5%) and Tween 20 (0.1%). The incubations with primary antibodies were 
performed at 4 °C for 12 h in blocking buffer (3% skim milk and 0.1% Tween in Tris-buffered 
saline). The membranes were then incubated with the corresponding counter-antibody and the 
proteins evidenced by enhanced chemiluminescence detection (ECL Plus System, GE Health Care, 
Little Chalfont, Buckinghamshire, UK). As primary antibodies the following were used: anti-BCL-
XL/S (sc-634); anti-BCL-2 (sc-492), anti-Actin (sc-1616-R), anti-p-p38 (sc-7973), anti-MKP-1 (sc-
1102) and anti-p38 (sc-535-G), from Santa Cruz Biotechnology (Santa Cruz, CA, USA). As 
secondary antibody a peroxidase labeled anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) was used. Densitometric analysis of protein levels was performed with ImageJ 1.34s 
software (Wayne Rasband, National Institutes of Health, USA. http://rsb.info.nih.gov/ij/). 
2.9. RNA analysis by RT-qPCR. RAW 264.7, LM3 and A549 cells were incubated for 24 h with 
steroids and 10 μg/ml LPS plus 100 U/ml IFN-γ or 10 ng/ml TNF-α,  respectively. LM3 cells were 
treated with different stimuli for 4 h. Total RNA was extracted with Trizol reagent according to the 
manufacturer’s instructions. For reverse transcription, 1 μg of total RNA was used. The first cDNA 
strand was synthesized with 200 U MMLV reverse transcriptase; 25 ng/l random primers; 2 g/l 
RNasin and 1.5 mM deoxynucleotide triphosphates. Retrotranscription was performed at 37 °C for 
60 min followed by 15 min at 72 °C. For the quantitative real-time RT-PCR (qRT-PCR), an aliquot 
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of 0.5 μl cDNA was used. All reactions were conducted in a volume of 25 μl containing 2 - 4 mM 
MgCl2, deoxynucleotide triphosphates 0.2 mM, Taq polymerase 0.75 U, Sybr Green 1:30, and 
specific oligonucleotides for each gene (as shown below) in a DNA Engine Opticon instrument (MJ 
Research, Waltham, MA). The oligonucleotides used for each gene were as follows: Bcl-XL, 5′-
AACGGCGGCTGGGAC-3′ and 5′-TGAAGAGTGAGCCCAGCAGAAC-3′;Bcl-2, 5´-
AGCAGGAGAGGAGGAACAG-3´ and 5´-GTAGATGGCGAACAGGAAGG-3´; COX-2, 5´-
TTCAAATGAGATTGTGGGAAAATTGCT-3´ and 5´-AGATCATCTCTGCCTGAGTATCTT-3´; 
IL-8, 5´-CTGCGCCAACACAGAAATTA-3´ and 5´-ATTGCATCTGGCAACCCTAC-3´; Nos-2, 
5´-TCAGACATGGCTTGCCCCTGGA-3´ and 5´-TGCCCCAGTTTTTGATCCTCACA-3´; human 
GAPDH, 5´-GAGTCAACGGATTTGGTCGT-3´ and 5´-TTGATTTTGGAGGGATCTCG-3´; and 
mouse Actin, 5′-CCACACCCGCCACCAGTTC-3′ and 5′-GACCCATTCCCACCATCACACC-3′. 
Reactions were run for 40 cycles under the following conditions: 25 s at 94 °C, 25 s at 58–65 °C 
(according to the primers), and 25 s at 72 °C. The amplification of unique products in each reaction 
was verified by melting curve and ethidium bromide (Sigma Aldrich)-stained agarose gel 
electrophoresis. The expression level of each gene was normalized to Actin or GAPDH expression 
level using standard curve method and specific primers. Results are expressed as mean ± standard 
deviation (SD) from at least three experiments, and shown as fold changes respect to basal values.  
2.10. Nitrite production. Nitric oxide (NO) levels were evaluated through the release of nitrite 
(NO2-) in the supernatants of peritoneal macrophages and RAW 264.7 cells cultured with 10 μg/ml 
LPS plus 100 U/ml IFN-gamma and 0.1 μΜ DEX or 10 μΜ 21OH-6,19OP for 24 h by the Griess 
reaction, as previously described [27]. Briefly, 100 μl of supernatants were incubated with an equal 
volume of the Griess reagent (NEED – N-ethyl-N-diamine 0.1% and sulfanilamide 1% in H3PO4 
5%) at room temperature, and the absorbance was evaluated at 540 nm using a microtiter plate 
spectrophotometer. The NO2- concentration was determined using a standard curve spanning from 1 
to 100 μM NO2-. 
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2.11. Statistical analysis. Results were expressed as means ± SE, as it is indicated in the figure 
legends. ANOVA followed by Tukey's multiple comparisons tests were used to detect significant 
differences among treatments. Statistical analyses were performed with Infostat (J.A. Di Rienzo, F. 
Casanoves, M.G. Balzarini, L. Gonzalez, M. Tablada, C.W. Robledo. InfoStat versión 2011. Grupo 
InfoStat, FCA, Universidad Nacional de Córdoba, Argentina. URL http://www.infostat.com.ar). 
Differences were regarded as significant if p < 0.05. Before, statistical analysis data were tested for 
normality and homoscedasticity using Shapiro-Wilks and Levene´s tests, respectively.  
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3. Results 
3.1. 21OH-6,19OP as a potential anti-inflammatory drug 
    To analyze the putative role of 21OH-6,19OP as an anti-inflammatory drug, we first evaluated 
the effects of 21OH-6,19OP on Nitric oxide (NO) production. NO acts as a messenger molecule 
mediating diverse inflammatory pathways [28]. In our system, NO was assessed by determining 
NO2- levels in supernatants of LPS/IFN-γ−activated peritoneal macrophages. Results from Figure 1 
show that 21OH-6,19OP (10-5M) inhibited LPS-induced nitrite production to basal levels, similarly 
to DEX (10-7M) (FIG. 1A). Although, a similar concentration-response relationship was obtained 
with the murine macrophage cell line RAW 264.7 treated with LPS/IFN-γ together with increasing 
amounts of 21OH-6,19OP, this compound seems to be less potent in these cells than in activated 
macrophages. In fact, 21OH-6,19OP inhibited nitrite formation in a concentration-dependent 
manner with an estimated IC50 of 55 μM in RAW264.7 cells (FIG. 1B). It is well known that NO is 
synthesized from L-arginine by three Nos isoforms. Nos-2 is one of the enzyme isoform that is 
mainly expressed in response to pro-inflammatory mediators. Thus, we evaluated whether 
inhibition of NO production by 21OH-6,19OP is a consequence on the regulation of NOS-2 gene 
expression. RAW 264.7 cells were incubated with LPS in the presence of 21OH-6,19OP (10-5M) or 
DEX (10-7M). After 24 h, cells were harvested and total RNA was prepared. The expression of 
NOS-2 was assessed by RT-qPCR using specific primers. LPS increased NOS-2 expression 33 fold 
above basal levels (FIG 2 A) and these were partially but significantly inhibited by 21OH-6,19OP. 
Thus, the ability of 21OH-6,19OP to inhibit NO could involve the down regulation of NOS-2 gene. 
   Other inflammation markers usually evaluated in different cell lines, are COX-2, that catalyses the 
synthesis of prostaglandins [29-30] and IL-8, a cytokine involved in neutrophil chemo-attraction 
and activation [31]. Both COX-2 and IL-8 gene expression are regulated by NF-κB [32-33] and AP-
1 [34-35] transcription factors. To test whether 21OH-6,19OP modulates their expression, A549 
lung cancer epithelial cells were treated with TNF-α in the absence or presence of 21OH-6,19OP 
Page 14 of 43
Ac
ce
pte
d M
an
us
cri
pt
14 
 
(10-5M) or DEX (10-7M) and total RNA was prepared and quantified by RT-qPCR. Results show 
that 21OH-6,19OP, similarly to DEX, completely blocks both COX-2 (FIG 2B) and IL-8 (FIG 2C) 
gene expression, supporting the anti-inflammatory effect of this compound.  
   The regulation of COX-2 expression was also assessed in vivo. Inflammation was provoked by 
injecting LPS (5 mg/kg, i.p.) into female BALB/c in the absence or presence of DEX (2 mg/kg) or 
21OH-6,19OP (25 mg/kg). After 16 h, animals were sacrificed and peritoneal macrophages were 
obtained. Then, total RNA was prepared and quantified by RT-qPCR. Similar to DEX, the steroid 
completely inhibited COX-2 expression induced by LPS, confirming the in vivo anti-inflammatory 
effect of this steroid (FIG. 2D). 
 
3.2. 21OH-6,19OP inhibits Cox-2 expression throughout p38 mitogen activated protein kinase 
inactivation  
    It is well known that GCs exert their anti-inflammatory effects mainly through the inhibition of 
NF-κB and AP-1 signaling pathways. In this sense, pRelA (the active subunit of NF-κB) and pc-Jun 
(a component of AP-1 factor) were transiently transfected in A549 cells treated or not with DEX or 
21OH-6,19OP. After transfections, COX-2 expression levels were assayed by RT-qPCR. As 
expected, DEX inhibited COX-2 expression induced by both RelA (FIG. 3A) or pcJun (FIG 3B) 
while the rigid steroid was ineffective, suggesting that in this cellular system 21OH-6,19-OP 
decreases COX-2 expression triggered by TNF-α by a different mechanism than that involving NF-
κB or AP-1 activities. 
    Taking into account that GCs also exert their anti-inflammatory effects through the regulation of 
p38 MAPK activity, we analyzed the effect of 21OH-6,19OP on p38 activation. Thus, western blots 
were performed in A549 cells treated with the cytokine TNF-α in the absence or presence of the 
rigid compound or DEX. As expected, phospho-p38 levels increased, roughly 2.5 fold, upon TNF-
α addition (FIG 4A, lane 2). This increment was inhibited by both DEX and 21OH-6,19OP (Figure 
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4A, lane 5 and 6, respectively). Cells were then co-incubated with TNF-α  without or with the 
steroids in the presence of Na2VO4 (NaOV), a dual phosphatase inhibitor. Results show that 
phospho-p38 levels were recovered when NaOV was added (Figure 4A, lanes 7 and 8), supporting 
the idea that in these cells, GCs would induce a p38 phosphatase. To further examine the 
involvement of dual phosphatases on 21OH-6,19OP effects, we quantified COX-2 expression levels 
from A549 cells treated with TNF-α and the rigid steroid in the presence of NaOV. Interestingly, 
inhibition of dual phosphatases completely blocked 21OH-6,19OP repression of TNF-α-dependent 
COX-2 expression (FIG 4B, compare lane 4 with lane 3). The inhibition of p38 activity with 
SB203580 (SB) (FIG 4B, lane 5) or its activation with anisomicin (ANISO) (FIG 4B, lane 6), 
reduced and increased Cox-2 expression, respectively. Together these results support the hypothesis 
that the rigid steroid would decrease Cox-2 expression mainly by reducing p38 phosphorylation. 
    Taking into account that the expression of the specific p38 phosphatase MKP-1 is regulated by 
GCs [35-39], we then evaluated MKP-1 expression by western blot assays. MKP-1 protein levels 
increased upon the addition of both 21OH-6,19OP or DEX to cells treated with TNF-α (FIG 4C), 
indicating that the rigid steroid would down-regulate COX-2 expression by inactivating p38 through 
the increase of MKP-1 levels. Together these results support the role of 21OH-6,19OP as a new anti-
inflammatory compound.  
 
3.3. 21OH-6,19OP does not induce chemoresistance to paclitaxel in mammary tumor cells 
    As mentioned above, synthetic GCs as DEX are often used as coadjuvants in the chemotherapy of 
solid tumors, such as mammary tumors. However, their use was also associated to chemoresistance 
induction, probably due to the anti-apoptotic effects of GCs in epithelial cells. In order to test 
whether the new steroid provokes resistance effects as DEX, murine mammary tumor cells LM3 
were treated with 10 μM PTX in the presence of 1 μM DEX or 10 μM 21OH-6,19OP during 36 h. 
The concentration of PTX was used according to MTT assays whose results showed that 10 μM 
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PTX inhibits at least 50 % cell viability (data not shown). After incubation, Caspase-3 activity was 
determined as a parameter of apoptosis. Figure 5A shows that while DEX significantly inhibited 
Caspase-3 activity provoked by the chemotherapeutic drug (Figure 5 A, lane 3 vs lane 2), 21OH-
6,19OP was unable to modify this protease activity (Figure 5 A, lane 4 vs lane 2). These results 
correlate with those obtained from crystal violet cell viability assays where 68% of the cells died in 
the presence of the antineoplastic drug but diminished to 58% in the presence of DEX, while in cells 
treated with PTX plus 21OH-6,19OP the percentage of death cells was 77% (Figure 5 B). 
    In mammary epithelial cells, Caspase-3 activity is mainly controlled by the activity of the anti-
apoptotic protein BCL-XL [40]. In this sense, RT-qPCR and western blot assays were performed in 
order to analyze the expression levels of BCL-XL in LM3 cells treated with PTX in the presence of 
DEX or 21OH-6,19-OP. Results shown in Figures 6 A and B indicate that DEX increases Bcl-XL 
transcript levels (2.8 fold vs. Control) and BCL-XL protein  (1.7 fold vs Control), independently of 
the presence of PTX. However, 21OH-6,19OP was unable to induce BCL-XL expression either alone 
or in the presence of PTX. Expression of the anti-apoptotic member BCL-2 was neither modified by 
the chemotherapeutic agent nor by the GCs (Figure 6 C and D). Together these results suggest that 
the rigid steroid, contrary to DEX, does not inhibit the induction of apoptosis by PTX in mammary 
tumor epithelial cells. 
    In order to investigate whether these results had an in vivo correlate, mammary tumor growth 
assays were performed in syngeneic BALB/c female mice. For this, animals were inoculated s.c with 
4 x 105 LM3 cells to induce tumor development and after 7 days, when tumors were palpable, mice 
were injected i.p. with PTX without or with DEX or 21OH-6,19OP. As shown in Figure 7 PTX 
significantly reduced LM3 tumor growth as compared with tumors in control animals treated with 
the vehicle alone. While the combined treatment with DEX prevented PTX–induced tumor growth 
inhibition, the rigid steroid did not affect PTX in vivo antitumoral activity (Fig. 7A). Statistical 
analyses of tumor size performed at days 7, 14 and 30 after cell inoculation support the idea that 
21OH-6,19-OP is not able to induce in vivo chemoresistance in mammary cells (Fig. 7B). 
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    Microscopic examination did not reveal any effect of treatments on the histopathological features 
of LM3 tumors, which maintained their adenocarcinoma poorly differentiated phenotype. However, 
we found that PTX induced a significant marked reduction in the number of mitotic figures (Fig. 
7C) as well as extensive areas of apoptotic and necrotic cells (data not shown). Interestingly, while 
DEX completely reverted PTX effect, 21OH-6,19OP did not affect it (Fig. 7C). 
    To evaluate whether these combined treatments could impair the potential antimetastatic activity 
of PTX, we analyzed the lung sections for the presence of parenchymal metastatic nodules. We 
found that PTX induced a significant reduction in metastasis incidence, from 75% in control mice to 
40 % in the treated ones. In agreement with their effects on s.c. tumor growth, 80 % of DEX-PTX 
treated mice developed metastases while only 20% of those treated with 21OH-6,19OP-PTX did so. 
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4. Discussion 
    GCs activities are a consequence of specific and independent glucocorticoid actions at various 
sites. Although the complex mechanisms by which GR regulates transcription is not completely 
understood, it is well known that these mechanisms involve the interaction of GR with proteins that 
make up the basal transcription apparatus. 
     In the present work we describe several anti-inflammatory actions of the synthetic steroid 21OH-
6,19OP. This compound, similar to the full GR agonist DEX and other dissociated GCs [38,41-44] 
has been demonstrated to inhibit the LPS/IFN-γ mediated NO formation in a concentration-
dependent manner and to repress NOS-2 and COX-2 gene expression in macrophages. 21OH-
6,19OP also inhibits TNF-α-induced COX-2 and IL-8 expression in human lung cancer A549 cells. 
In fact, our results are similar to those reported with Mapracorat, a non-steroidal GR selective 
ligand that inhibits COX-2 expression and p38 activation in RAW 264.7 cells [37] and IL-6, IL-8 
and G-CSF secretion in different types of ocular cells [41]. 21OH-6,19OP also behaves similar to 
RU24858, a dissociated steroid analog that inhibits nitrite formation induced by LPS in 
macrophages [43] and COX-2 expression as well as activity and IL-8 secretion induced by IL-1β in 
A549 cells [42]. Like DEX and RU24958, 21OH-6,19OP also partially reduces NOS-2 transcript 
levels [43]. Taking into account  that these steroids presented strong inhibitory effects on NO 
formation , the apparent dissimilar result observed when comparing with  glucocorticoid dependent 
NOS-2 decrease may be explained by glucocorticoid mediated post-transcriptional events that lead 
to Nos-2 protein degradation [45-46].  
The anti-inflammatory effects carried out by GCs involve several simultaneous pathways 
triggered by the activated GR. These include both mechanisms, the GR-mediated tethering of 
transcription factors and the transactivation of anti-inflammatory proteins. According to our results, 
the pathways triggered upon DEX or 21OH-6,19OP binding to GR, seem to be slightly dissimilar. 
While COX-2 and IL-8 expression levels are controlled by the DEX-activated GR at different sites, 
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i.e. by direct tethering of NF-κB and AP-1 transcription factors [35,47], by down-regulating the p38 
activity through the induction of MKP-1 phosphatase [48] and by inducing the expression of factors 
involved in controlling mRNA stability [49], 21-OH-6,19OP was unable to repress pRelA- and 
pcJun-dependent COX-2 induction but it did increase MKP-1 protein levels and consequently led to 
a decrease in COX-2 levels by p38 inactivation in A549 cells. This suggests a certain tissue 
selectivity of this compound towards the up-regulation of the MKP-1 mediated pathway over the 
direct transrepression mechanism, in accordance with the fact that the rigid steroid was shown to 
inhibit NF-κB and AP-1 activities in other cell types [15-16]. 
    Taking into account that most of the anti-inflammatory and immune-suppressive actions of 
dissociated GCs involve the negative regulation of gene expression throughout the direct GR-
mediated tethering of transcription factors, being the most-studied crosstalk mechanisms of those 
between GR and NF-κB and AP-1 [29,41,50-53], this selective behavior of the GR/21OH-6,19OP 
complex observed in lung cancer epithelial cells makes this compound a potential therapeutic drug. 
Besides, it is interesting to note that 21OH-6,19OP incapacity to trigger the GR-mediated 
transrepression mechanism might be also inherent to the incapacity of the GR/21OH-6,19OP 
complex to recruit some transcription co-modulators. In fact, upon binding of 21OH-6,19OP, the 
GR has been shown to be unable to recruit TIF2, a co-activator involved in GR mediated direct 
transactivation of certain genes and transrepression of NF-κB [47]. 
     Whereas MKP-1 is one of the few GC-inducible genes mediating some of the anti-
inflammatory properties of GR, many other genes positively regulated by GR would also play a 
putative role in mediating 21OH-6,19OP actions [54-57]. In this sense, further studies are necessary 
to evaluate the effects of 21OH-6,19OP on the induction of other anti-inflammatory factors. 
Nevertheless, identification of those genes and their functionality is still far from being fully 
understood, indicating the complexity of the anti-inflammatory roles of the GR. 
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   How GCs regulate MKP-1 expression is still a matter of discussion. In fact, Johansson-Haque et 
al. have suggested that the GR would activate MKP-1 promoter by its indirect recruitment to 
C/EBPβ response elements, since DEX addition to a GR variant unable to directly transactivate 
gene expression, was found to maintain its ability to induce MKP-1 trough the C/EBPβ elements 
present in the promoter [58]. On the other hand, ChIP experiments have also been demonstrated to 
recruit GR to specific GREs located in the promoter region of MKP-1 [39]. Therefore, at least two 
mechanisms could be involved simultaneously in the induction of MKP-1 by GCs. Moreover, 
although studies performed using the knock-in of a GRdim mutant mouse suggested that 
dimerization of GR is necessary for MKP-1 induction [59], it was also demonstrated that the 
GRdim/DEX complexes provoked an increase in MKP-1 levels in macrophages [48]. Nevertheless, 
the ability of the GRdim/DEX mutant to dimerize is actually under revision. Taking into account 
that the GR/21OH-6,19OP was able to dimerize but unable to induce the expression of genes driven 
by GREs [15], it seems possible that the increased levels of MKP-1 could be a consequence of the 
indirect transactivation pathway triggered by the rigid compound. 
As we mentioned above, like others dissociated glucocorticoids 21OH-6,19OP is unable to induce 
the direct GR/GRE action [44]. In this sense, it was demonstrated that VBP1, a Δ-9,11 analog, was 
more effective than full agonists, to down-regulate anti-inflammatory genes whose promoters 
contain both GREs and NF-κB promoter elements, probably due to incapacity of the GR to directly 
bind DNA [44]. This would not be the case for this rigid compound, since GR/21OH-5,19OP 
complexes bind DNA [60]. 
   Taken together, these results support the idea that 21OH-6,19OP exerts its anti-inflammatory 
effects by regulating only some of the pathways involved in the GR cellular response. 
   In the present work we also demonstrate that 21OH-6,19OP, contrary to DEX, was unable to 
induce chemoresistance in the LM3 cell line treated with PTX, a murine mammary tumor model, 
both in vitro and in vivo. It is worth mentioning that similar results were obtained in LM3 cells 
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treated with the anthracycline doxorubicin. In fact, DEX (1 μM) inhibited cell death triggered by 10 
μM doxorubicin, whereas 21OH-6,19OP (10 μM) did not affect it (AJ Orqueda, personal 
communication). The lack of effect observed in tumor mammary cells treated with this compound 
makes it a good candidate to be used in anti-neoplastic regimes, although before leaping to human 
application, further experiments with other chemotherapy agents and other cancer cell types should 
be performed. The inability of 21OH-6,19OP to prevent cell death correlates with its failure to 
prevent PTX-dependent caspase-3 activation and to induce the expression of the anti-apoptotic 
BCL-XL isoform. Glucocorticoid-dependent up-regulation of BCL-XL was also observed in the 
murine mammary epithelial cells HC11 by a mechanism that involves the recruitment of the 
activated GR to specific GREs located at the promoter region of the gene [22,61-62]. 
    The anti-apoptotic effect of GCs in the mammary gland has been associated with the inhibition of 
Caspases-3, -7 and -8 activities and the decrease of AP-1 dependent transcription [63-64]. 
Moreover, in chemotherapy-treated breast cancer cells, GCs also prevent cell death by a mechanism 
that involves SGK-1 and MPK-1 kinases [65]. Interestingly, in these cells GCs induce cell-cycle 
arrest and increase expression of the cell-cycle inhibitors p21CIP1 and p27KIP1 [66-68]. 
Considering the DNA damaging action of chemotherapeutic drugs, death resistance produced by 
GCs may be an epiphenomenon of cell-cycle inhibition, since arrested cells are not 
chemotherapeutic targets. Therefore, glucocorticoid-induced chemotherapy resistance might occur 
together with tumor-suppressor and anti-apoptotic gene induction. 
    In summary, the above results suggest that 21OH-6,19OP conserves the so-called beneficial 
glucocorticoid properties by regulating only some of the pathways triggered by the GR. It is now 
well established that the ability of ligands to regulate gene expression is influenced by both the 
identity and relative expression of receptor co-activators and co-repressors [69]. In fact, increasing 
evidence suggests that the effects of GCs depend significantly on the co-regulators interacting with 
the receptor, rather than on the state of GR oligomerization or GR ability to bind DNA [60]. The 
design of new GCs able to provoke the recruitment of specific co-activator subsets by determined 
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GR conformations acquired upon ligand binding is thus highly desirable. 21OH-6,19OP binding to 
GR induces subtle conformational changes in the receptor [16]. These compounds would modulate 
the recruitment of certain co-factors, which consequently would lead to the activation of only a 
subset of GR functions. In this sense, 21OH-6,19OP arises as a dissociated GC with potential 
therapeutic effects. 
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Figure Legends 
Figure 1. 21OH-6,19OP exerts GC anti-inflammatory effects. A. Peritoneal macrophages were 
stimulated with 10 μg/ml LPS and 100 U/ml IFN-γ, and 10 μM 21OH-6,19OP or 0.1 μM DEX as 
control. After 24 h nitrite production was quantified by the Griess reaction. Values were expressed 
as μM concentration ± SE from three independent experiments. *P < 0.05. B. RAW 264.7 
macrophage tumor cells were incubated with 10 μg/ml LPS and 100 U/ml IFN-γ, and 1 - 100 μM 
21OH-6,19OP. After 24 h nitrites production was quantified by the Griess reaction. Values are 
expressed as fold change relative to the LPS + IFN-γ treatment. 
 
Figure 2. 21OH-6,19OP, similarly to DEX, inhibits TNF-α induced expression of NOS-2 (A), 
COX-2 (B and D) and IL-8 (C). A. RAW 264.7 cells were incubated with 10 μg/ml LPS and 100 
U/ml IFN-γ, and 10 μM 21OH-6,19OP or 0.1 μM DEX for 24 h. Then, total RNA was extracted 
and the levels of NOS-2 mRNA were quantified by RT-qPCR. Mean ± SE values of NOS-2 relative 
to actin levels are shown. B and C. A549 lung cancer cells were incubated with 10 ng/ml TNF-α 
and 10 μM 21OH-6,19OP or 0.1 μM DEX. After 24 h COX-2 (B) and IL-8 (C) mRNA levels were 
measured by RT-qPCR. Mean ± SE values of COX-2 or IL-8 relative to GAPDH levels from three 
independent experiments are shown. D. Adult female BALB/c mice were injected intraperitoneally 
with 5 mg/kg LPS without or with 2 mg/kg DEX or 25 mg/kg 21OH-6,19OP. Sixteen hours later, 
peritoneal macrophages were collected and COX-2 mRNA levels were quantified by RT-qPCR. 
Mean ± SE values of Cox-2 relative to actin levels are shown, n = 6. *P < 0.05. 
 
Figure 3. 21OH-6,19OP inhibitory effects are independent of Rel A and AP-1 pathways. A549 cells 
transfected with pRelA (A) or pcJun (B) expression vectors were incubated with 0.1 μM DEX or 10 
μM 21OH-6,19OP. After 16 h total RNA was collected and COX-2 mRNA levels were determined 
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by RT-qPCR. Mean ± SE values of COX-2 mRNA levels relative to GAPDH from three 
independent experiments are shown. *P < 0.05. 
 
Figure 4. MKP-1-dependent effects of 21OH-6,19OP on COX-2 expression. 21OH-6,19OP 
modulates MKP-1 activity. A. A549 cells were incubated with 10 ng/ml TNF- α and 10 μM 21OH-
6,19OP or 0.1 μM DEX for 2 h. Then, activated p38 protein levels were determined by western blot 
assay. A representative image (upper panel) and the mean values of phospho-p38 relative to p38 
protein levels ± SE from three independent experiments (lower panel) are shown. B. A549 ells were 
incubated with 10 ng/ml TNF- α, with or without 10 μM 21OH-6,19OP and 100 μM NaOV. 
Treatments with the p38 inhibitor SB203580 (SB) or the p38 activator anisomicin (ANISO) were 
also performed. Twenty four hours later total RNA was collected, and COX-2 mRNA levels were 
determined by RT-qPCR. Mean ± SE values of COX-2 mRNA levels relative to GAPDH from three 
independent experiments are shown. C. A549 cells were incubated with 10 ng/ml TNF- α and 10 
μM 21OH-6,19OP or 0.1 μM DEX. After 2 h MKP-1 protein levels were determined by western 
blot. A representative image (upper panel) and the mean values of MKP-1 protein levels relative to 
actin ± SE from three independent experiments (lower panel) are shown. *P < 0.05. 
 
Figure 5. 21OH-6,19OP does not inhibit apoptosis triggered by PTX in mammary tumor cells. A. 
LM3 mammary tumor cells were treated with 10 μM PTX and 10 μM 21OOH-6,19OP or 1 μM 
DEX for 36 h. Caspase-3 like enzymatic activity was determined by quantifying the absorbance of 
the chromophore pNA at 415 nm; the cleavage activity was expressed as pNA absorbance units/mg 
protein ± SE. B. Cell viability was quantified by crystal violet staining in LM3 cells incubated in 
the presence of 10 μM PTX and 10 μM 21OH-6,19OP or 1 μM DEX for 48 h. Data are plotted as 
% cell viability ± SE. n = 4, *P < 0.05. 
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Figure 6. 21OH-6,19OP does not increase BCL-XL levels in mammary tumor cells. LM3 cells were 
stimulated with 10 μM PTX and 10 μM 21OH-6,19OP or 1 μM DEX. After 4h, total RNA was 
collected and Bcl-XL and Bcl-2 mRNA levels were determined by RT-qPCR (A and C, 
respectively). Mean ± SE values of Bcl-XL and Bcl-2 mRNA levels, both relative to actin, are 
shown. Proteins were extracted after 5 h treatments, and BCL-XL and BCL-2 levels were 
determined by Western blot assays (B and D, respectively). A representative image (upper panel) 
and the mean ± SE values of BCL-XL and BCL-2 protein levels, both relative to actin, are shown. n 
= 3, *P < 0.05. 
 
Figure 7. 21OH-6,19OP does not decrease the effectiveness of PTX on LM3 tumors. A. LM3 cells 
(4x105) were injected s.c. into the left flank of 12 week old female BALB/c mice. Seven days later, 
mice were randomly divided into four treatment groups: Vehicle; PTX (10 mg/kg/day); 21OH-
6,19OP (25 mg/kg/day) + PTX; and DEX (0.2 mg/kg/day) + PTX. Tumor dimensions were 
measured 3 times every week with calipers and two perpendicular diameters (width, w, and length, 
l) were determined; D parameters were calculated according to the equation: lwD ⋅= . B. 
Details of the results obtained at days 7, 14 and 30, corresponding to those used in the ANOVA for 
repeated measures, are shown. Error bars represent SE. n = 3,*P < 0.05. C. Mitotic figures from 
H&E stained sections of LM3 tumors (three fields from each sample) were counted using a 
conventional light microscope. Data are plotted as % mitotic cells ± SE. n = 5, *P < 0.05.
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